avelumab,cabozantinib
pfizer,exelixis,merck
['improve', 'atlantis', 'bladder', 'cabozantinib', 'avelumab']
#asco22 atlantis trial with cabozantinib as maintenance therapy reinforce the data from javelin bladder 101 of avelumab as standard 1st line approach in muc. not even close to chase improvement in os so far and comparator arm outcome resembles and matched what found at javelin 
Jefe del Servicio de #Oncología Médica y Director de Investigación Clínica de la Fundación MD Anderson Cancer Center Madrid. Opinions are my own